158
Views
0
CrossRef citations to date
0
Altmetric
Articles

Variation of meningioma in response to cyproterone acetate in a trans woman

, , , &

References

  • Benson, V. S., Kirichek, O., Beral, V., & Green, J. (2015). Menopausal hormone therapy and central nervous system tumor risk: Large UK prospective study and meta-analysis. International journal of cancer, 136(10), 2369–2377. doi:10.1002/ijc.29274
  • Bergoglio, M. T., Gomez-Balaguer, M., Almonacid Folch, E., Hurtado Murillo, F., & Hernandez-Mijares, A. (2013). Symptomatic meningioma induced by cross-sex hormone treatment in a male-to-female transsexual. Endocrinology and Nutrition, 60(5), 264–267. doi:10.1016/j.endonu.2012.07.004
  • Cebula, H., Pham, T. Q., Boyer, P., & Froelich, S. (2010). Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient. Acta Neurochirurgica, 152(11), 1955–1956. doi:10.1007/s00701-010-0787-2
  • Fung, R., Hellstern-Layefsky, M., & Lega, I. (2017). Is a lower dose of cyproterone acetate as effective at testosterone suppression in transgender women as higher doses? International Journal of Transgenderism, 18(2), 123–128. doi:10.1080/15532739.2017.1290566
  • Gazzeri, R., Galarza, M., & Gazzeri, G. (2007). Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. New England Journal of Medicine, 357(23), 2411–2412. doi:10.1056/NEJMc071938
  • Knight, E. J., & McDonald, M. J. (2013). Recurrence and progression of meningioma in male-to-female transgender individuals during exogenous hormone use. International Journal of Transgenderism, 14(1), 18–23. doi:10.1080/15532739.2012.725563
  • Meriggiola, M. C., & Gava, G. (2015). Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. Clinical Endocrinology, 83(5), 607–615. doi:10.1111/cen.12754
  • Speirs, V., Boyle-Walsh, E., & Fraser, W. D. (1997). Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response of in vitro cell cultures to steroid hormones. International Journal of Cancer, 72(5), 714–719. doi:10.1002/(SICI)1097-0215(19970904)72:5%3c714::AID-IJC2%3e3.0.CO;2-V
  • Ter Wengel, V. P., Martin, E., Gooren, L., Den Heijer, M., & Peerdeman, S. M. (2016). Meningiomas in three male-to-female transgender subjects using oestrogens/progestogens and review of the literature. Andrologia, 48(10), 1130–1137. doi:10.1111/and.12550
  • Wierckx, K., Mueller, S., Weyers, S., Van Caenegem, E., Roef, G., Heylens, G., & T'Sjoen, G. (2012). Long-term evaluation of cross-sex hormone treatment in transsexual persons. Journal of Sexual Medicine, 9(10), 2641–2651. doi:10.1111/j.1743-6109.2012.02876.x
  • Wigertz, A., Lonn, S., Mathiesen, T., Ahlbom, A., Hall, P., Feychting, M., & Swedish Interphone Study, G. (2006). Risk of brain tumors associated with exposure to exogenous female sex hormones. American Journal of Epidemiology, 164(7), 629–636. doi:10.1093/aje/kwj254

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.